Literature DB >> 12898034

[Non-invasive urinary diagnosis of bladder cancer. What do we know?].

I Kausch1, A Böhle.   

Abstract

Although the current system of classifying bladder cancer by stage and histological grade is very useful, it is still difficult to predict the natural progression of the disease either with or without therapy. Cystoscopy and urine cytology are currently the gold standards in the monitoring and diagnosis of bladder cancer. Classical urine cytology is, however, at least in the diagnosis of G1-tumors, characterized by a relatively low sensitivity. In the last few years, the molecular biological investigation of the basic mechanisms involved in carcinogenesis has provided a host of markers which are of potential diagnostic value for bladder cancer. We provide a current, comprehensive review of the literature on bladder tumor markers and summarize their diagnostic and prognostic potential. At present, no diagnostic marker with a comparable sensitivity and specificity to cystoscopy exists, given that cystoscopy has never been evaluated. The combined analysis of several tumor markers seems to be the most promising approach as an adjunct to cystoscopy. Moreover, the increasing simplification of test systems will increase their acceptance by clinicians.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898034     DOI: 10.1007/s00120-003-0307-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  68 in total

1.  New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer.

Authors:  M Sánchez-Carbayo; A Espasa; V Chinchilla; E Herrero; J Megías; A Mira; F Soria
Journal:  Clin Chem       Date:  1999-11       Impact factor: 8.327

2.  Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.

Authors:  H T Pham; N L Block; V B Lokeshwar
Journal:  Cancer Res       Date:  1997-02-15       Impact factor: 12.701

3.  Improved detection of recurrent bladder cancer using the Bard BTA stat Test.

Authors:  M F Sarosdy; M A Hudson; W J Ellis; M S Soloway; R deVere White; J Sheinfeld; M V Jarowenko; P F Schellhammer; E W Schervish; J V Patel; G W Chodak; D L Lamm; R D Johnson; M Henderson; G Adams; B A Blumenstein; K R Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle
Journal:  Urology       Date:  1997-09       Impact factor: 2.649

4.  Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation.

Authors:  J Sheinfeld; V E Reuter; M R Melamed; W R Fair; M Morse; P C Sogani; H W Herr; W F Whitmore; C Cordon-Cardo
Journal:  J Urol       Date:  1990-02       Impact factor: 7.450

5.  Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial.

Authors:  B W van Rhijn; I Lurkin; W J Kirkels; T H van der Kwast; E C Zwarthoff
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

6.  Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.

Authors:  A Giannopoulos; T Manousakas; A Gounari; C Constantinides; H Choremi-Papadopoulou; C Dimopoulos
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

7.  Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer.

Authors:  A Schneider; S Borgnat; H Lang; O Régine; V Lindner; M Kassem; C Saussine; P Oudet; D Jacqmin; M P Gaub
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

8.  Telomerase activity in human urothelial tumors.

Authors:  S Kyo; K Kunimi; T Uchibayashi; M Namiki; M Inoue
Journal:  Am J Clin Pathol       Date:  1997-05       Impact factor: 2.493

9.  Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis.

Authors:  J Y Rao; G P Hemstreet; R E Hurst; R B Bonner; P L Jones; K W Min; Y Fradet
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

10.  Bladder cancer-associated nuclear matrix proteins.

Authors:  R H Getzenberg; B R Konety; T A Oeler; M M Quigley; A Hakam; M J Becich; R R Bahnson
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.